FLT3 and acute myeloid leukemia: In contrast, co-treatment with AZD1208 did not sensitize primary AML patient cells with FLT3-WT (Figure 2B) or remission bone marrow cells (Figure 2C) to apoptosis induction by topoisomerase 2 inhibitors.